Cytosorbents Crp Stock Current Asset
| CTSO Stock | USD 0.88 0.01 1.15% |
Cytosorbents Crp fundamentals help investors to digest information that contributes to Cytosorbents Crp's financial success or failures. It also enables traders to predict the movement of Cytosorbents Stock. The fundamental analysis module provides a way to measure Cytosorbents Crp's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cytosorbents Crp stock.
As of the 12th of December 2024, Non Current Assets Total is likely to grow to about 28.9 M, while Total Current Assets are likely to drop about 17.6 M. Cytosorbents | Current Asset |
Cytosorbents Crp Company Current Asset Analysis
Cytosorbents Crp's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Cytosorbents Crp Current Asset | 9.05 M |
Most of Cytosorbents Crp's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytosorbents Crp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cytosorbents Current Asset Historical Pattern
Today, most investors in Cytosorbents Crp Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Cytosorbents Crp's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Cytosorbents Crp current asset as a starting point in their analysis.
Cytosorbents Crp Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Cytosorbents Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Cytosorbents Crp has a Current Asset of 9.05 M. This is 99.58% lower than that of the Health Care Equipment & Supplies sector and 99.55% lower than that of the Health Care industry. The current asset for all United States stocks is 99.9% higher than that of the company.
Cytosorbents Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytosorbents Crp's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cytosorbents Crp could also be used in its relative valuation, which is a method of valuing Cytosorbents Crp by comparing valuation metrics of similar companies.Cytosorbents Crp is currently under evaluation in current asset category among its peers.
Cytosorbents Crp Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cytosorbents Crp from analyzing Cytosorbents Crp's financial statements. These drivers represent accounts that assess Cytosorbents Crp's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cytosorbents Crp's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 124.2M | 309.4M | 181.7M | 67.5M | 49.6M | 47.1M | |
| Enterprise Value | 128.1M | 239.0M | 143.4M | 63.6M | 53.8M | 93.7M |
Cytosorbents Fundamentals
| Return On Equity | -1.18 | ||||
| Return On Asset | -0.28 | ||||
| Profit Margin | (0.49) % | ||||
| Operating Margin | (0.46) % | ||||
| Current Valuation | 68.78 M | ||||
| Shares Outstanding | 54.68 M | ||||
| Shares Owned By Insiders | 3.81 % | ||||
| Shares Owned By Institutions | 33.28 % | ||||
| Number Of Shares Shorted | 1.37 M | ||||
| Price To Earning | (16.30) X | ||||
| Price To Book | 3.67 X | ||||
| Price To Sales | 1.28 X | ||||
| Revenue | 36.35 M | ||||
| Gross Profit | 20.73 M | ||||
| EBITDA | (28.81 M) | ||||
| Net Income | (28.51 M) | ||||
| Cash And Equivalents | 30.16 M | ||||
| Cash Per Share | 0.69 X | ||||
| Total Debt | 18.31 M | ||||
| Debt To Equity | 0.28 % | ||||
| Current Ratio | 3.95 X | ||||
| Book Value Per Share | 0.24 X | ||||
| Cash Flow From Operations | (21.66 M) | ||||
| Short Ratio | 9.57 X | ||||
| Earnings Per Share | (0.36) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 186 | ||||
| Beta | 0.56 | ||||
| Market Capitalization | 48.16 M | ||||
| Total Asset | 53.26 M | ||||
| Retained Earnings | (282.51 M) | ||||
| Working Capital | 11.16 M | ||||
| Current Asset | 9.05 M | ||||
| Current Liabilities | 5 M | ||||
| Net Asset | 53.26 M |
About Cytosorbents Crp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytosorbents Crp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytosorbents Crp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytosorbents Crp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Cytosorbents Crp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytosorbents Crp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytosorbents Crp will appreciate offsetting losses from the drop in the long position's value.Moving together with Cytosorbents Stock
| 0.63 | CI | Cigna Corp Downward Rally | PairCorr |
Moving against Cytosorbents Stock
| 0.79 | MD | Mednax Inc | PairCorr |
| 0.79 | ECOR | Electrocore LLC | PairCorr |
| 0.7 | VREX | Varex Imaging Corp | PairCorr |
| 0.58 | LH | Laboratory | PairCorr |
| 0.55 | DXCM | DexCom Inc | PairCorr |
The ability to find closely correlated positions to Cytosorbents Crp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytosorbents Crp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytosorbents Crp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytosorbents Crp to buy it.
The correlation of Cytosorbents Crp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytosorbents Crp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytosorbents Crp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytosorbents Crp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Cytosorbents Crp Piotroski F Score and Cytosorbents Crp Altman Z Score analysis. To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.36) | Revenue Per Share 0.72 | Quarterly Revenue Growth 0.066 | Return On Assets (0.28) | Return On Equity (1.19) |
The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.